NA Non-Hodgkin Lymphoma Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

The North America Non-Hodgkin lymphoma diagnostics market is projected to register a substantial CAGR of 9.1% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

North America Non-Hodgkin Lymphoma Diagnostics Market, By Test Type (Imaging, Biopsy, Immunohistochemistry, Biomarker Test, Genetic Test, Cytogenetics, Lumbar Puncture (Spinal Tap), Blood Test and Cytochemistry), Cancer Stage (Stage IV, Stage III, Stage II, Stage I, and Stage 0), Tumor Type (Aggressive Lymphomas and Indolent Lymphomas), Product (Instrument Based Products, Platform Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the North America Non-Hodgkin lymphoma diagnostics market are:

Increased growth in the prevalence of Non-Hodgkin Lymphoma

Advancement in artificial intelligence in the diagnosis of Non-Hodgkin Lymphoma

Market Players:

Some of the major players operating in the North America Non-Hodgkin lymphoma diagnostics market are:

CANON MEDICAL SYSTEMS CORPORATION

Koninklijke Philips N.V.

Siemens Healthcare GmbH

Danaher.

Bio-Rad Laboratories, Inc.

General Electric Company

Sysmex Corporation

Grail

F. Hoffmann-La Roche

Neusoft Corporation

Agilent Technologies, Inc.

NeoGenomics Laboratories

Hologic, Inc

Integrated DNA Technologies, Inc.

CENTOGENE N.V.

Merit Medical Systems

Invitae Corporation

PerkinElmer Inc.

QIAGEN

GeneDx, LLC

1 INTRODUCTION 83

1.1 OBJECTIVES OF THE STUDY 83
1.2 MARKET DEFINITION 83
1.3 OVERVIEW OF THE NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET 83
1.4 LIMITATIONS 85
1.5 MARKETS COVERED 86

2 MARKET SEGMENTATION 89

2.1 MARKETS COVERED 89
2.2 GEOGRAPHICAL SCOPE 90
2.3 YEARS CONSIDERED FOR THE STUDY 91
2.4 CURRENCY AND PRICING 91
2.5 DBMR TRIPOD DATA VALIDATION MODEL 92
2.6 MULTIVARIATE MODELLING 95
2.7 PRODUCT TYPE LIFELINE CURVE 95
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 96
2.9 DBMR MARKET POSITION GRID 97
2.10 MARKET APPLICATION COVERAGE GRID 98
2.11 VENDOR SHARE ANALYSIS 99
2.12 SECONDARY SOURCES 100
2.13 ASSUMPTIONS 100

3 EXECUTIVE SUMMARY 101

4 PREMIUM INSIGHTS 104

4.1 PESTEL ANALYSIS 105
4.2 PORTER'S 5 FORCES 106

5 INDUSTRY INSIGHTS 107

6 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, REGULATIONS 108

7 MARKET OVERVIEW 110

7.1 DRIVERS 112
- 7.1.1 INCREASED GROWTH IN PREVALENCE OF NON-HODGKIN LYMPHOMA 112
- 7.1.2 INCREASE IN AWARENESS REGARDING NON-HODGKIN LYMPHOMA 112
- 7.1.3 ADVANCEMENT IN ARTIFICIAL INTELLIGENCE IN DIAGNOSIS OF NON-HODGKIN LYMPHOMA 112
- 7.1.4 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UP 113
7.2 RESTRAINTS 113
- 7.2.1 LACK OF AVAILABILITY OF TRAINED AND SKILLED MEDICAL PROFESSIONALS 113
- 7.2.2 STRINGENT REGULATIONS AND GUIDELINES FOR DIFFERENT TREATMENTS AND DIAGNOSIS 114
7.3 OPPORTUNITIES 115
- 7.3.1 TECHNICAL ADVANCEMENTS IN CANCER DIAGNOSIS 115
- 7.3.2 INCREASING HEALTHCARE EXPENDITURE IN CANCER R&D 115
- 7.3.3 GROWING INITIATIVES BY GOVERNMENT AND KEY PLAYERS 115
7.4 CHALLENGES 116
- 7.4.1 LACK OF EARLY DIAGNOSTIC AWARENESS AMONG PEOPLE 116
- 7.4.2 HIGH DIAGNOSTIC COST AND FEAR OF TREATMENT 116
- 7.4.3 COMMON MISDIAGNOSIS OF NON-HODGKIN LYMPHOMA (NHL) 117

8 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TEST TYPE 118

8.1 OVERVIEW 119
8.2 IMAGING 122
- 8.2.1 COMPUTED TOMOGRAPHY (CT) 123
- 8.2.2 CHEST X-RAY 123
- 8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 123
- 8.2.4 ULTRASOUND 123
- 8.2.5 POSITRON EMISSION TOMOGRAPHY (PET) 123
8.3 BIOPSY 123
- 8.3.1 EXCISIONAL OR INCISIONAL BIOPSY 124
- 8.3.2 CORE NEEDLE BIOPSY 124
8.4 IMMUNOHISTOCHEMISTRY 124
8.5 BIOMARKER TEST 125
- 8.5.1 BETA 2-M 126
- 8.5.2 LDH 126
- 8.5.3 CA-125 126
- 8.5.4 TP53 126
- 8.5.5 NPM1 127
- 8.5.6 OTHERS 127
8.6 GENETIC TEST 127
8.7 CYTOGENETICS 127
8.8 LUMBAR PUNCTURE (SPINAL TAP) 128
8.9 BLOOD TEST 129
8.10 CYTOCHEMISTRY 129
8.11 OTHERS 130

9 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TUMOR TYPE 131

9.1 OVERVIEW 132
9.2 AGGRESSIVE LYMPHOMAS 134
- 9.2.1 DIFFUSE LARGE B CELL LYMPHOMA 135
  - 9.2.1.1 INSTRUMENT BASED PRODUCTS 136
  - 9.2.1.2 PLATFORM BASED PRODUCTS 136
  - 9.2.1.3 KITS AND REAGENTS 136
  - 9.2.1.4 OTHER CONSUMABLES 136
- 9.2.2 ANAPLASTIC LARGE-CELL LYMPHOMA 136
  - 9.2.2.1 INSTRUMENT BASED PRODUCTS 137
  - 9.2.2.2 PLATFORM BASED PRODUCTS 137
  - 9.2.2.3 KITS AND REAGENTS 137
  - 9.2.2.4 OTHER CONSUMABLES 137
- 9.2.3 MANTLE CELL LYMPHOMA 137
  - 9.2.3.1 INSTRUMENT BASED PRODUCTS 138
  - 9.2.3.2 PLATFORM BASED PRODUCTS 138
  - 9.2.3.3 KITS AND REAGENTS 138
  - 9.2.3.4 OTHER CONSUMABLES 138
- 9.2.4 PERIPHERAL T-CELL LYMPHOMA 138
  - 9.2.4.1 INSTRUMENT BASED PRODUCTS 139
  - 9.2.4.2 PLATFORM BASED PRODUCTS 139
  - 9.2.4.3 KITS AND REAGENTS 139
  - 9.2.4.4 OTHER CONSUMABLES 139
- 9.2.5 LYMPHOBLASTIC LYMPHOMA 139
  - 9.2.5.1 INSTRUMENT BASED PRODUCTS 140
  - 9.2.5.2 PLATFORM BASED PRODUCTS 140
  - 9.2.5.3 KITS AND REAGENTS 140
  - 9.2.5.4 OTHER CONSUMABLES 140
- 9.2.6 BURKITT LYMPHOMA 140
  - 9.2.6.1 INSTRUMENT BASED PRODUCTS 141
  - 9.2.6.2 PLATFORM BASED PRODUCTS 141
  - 9.2.6.3 KITS AND REAGENTS 141
  - 9.2.6.4 OTHER CONSUMABLES 141
9.3 INDOLENT LYMPHOMAS 141
- 9.3.1 FOLLICULAR LYMPHOMA 142
  - 9.3.1.1 INSTRUMENT BASED PRODUCTS 143
  - 9.3.1.2 PLATFORM BASED PRODUCTS 143
  - 9.3.1.3 KITS AND REAGENTS 143
  - 9.3.1.4 OTHER CONSUMABLES 143
- 9.3.2 CUTANEOUS T-CELL LYMPHOMA 143
  - 9.3.2.1 INSTRUMENT BASED PRODUCTS 144
  - 9.3.2.2 PLATFORM BASED PRODUCTS 144
  - 9.3.2.3 KITS AND REAGENTS 144
  - 9.3.2.4 OTHER CONSUMABLES 144
- 9.3.3 MARGINAL ZONE B CELL LYMPHOMA 144
  - 9.3.3.1 INSTRUMENT BASED PRODUCTS 145
  - 9.3.3.2 PLATFORM BASED PRODUCTS 145
  - 9.3.3.3 KITS AND REAGENTS 145
  - 9.3.3.4 OTHER CONSUMABLES 145
- 9.3.4 LYMPHOPLASMACYTIC LYMPHOMA 145
  - 9.3.4.1 INSTRUMENT BASED PRODUCTS 146
  - 9.3.4.2 PLATFORM BASED PRODUCTS 146
  - 9.3.4.3 KITS AND REAGENTS 146
  - 9.3.4.4 OTHER CONSUMABLES 146
- 9.3.5 SMALL-CELL LYMPHOCYTIC LYMPHOMA 146
  - 9.3.5.1 INSTRUMENT BASED PRODUCTS 147
  - 9.3.5.2 PLATFORM BASED PRODUCTS 147
  - 9.3.5.3 KITS AND REAGENTS 147
  - 9.3.5.4 OTHER CONSUMABLES 147

10 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY APPLICATION 148

10.1 OVERVIEW 149
10.2 SCREENING 151
- 10.2.1 INSTRUMENT BASED PRODUCTS 152
- 10.2.2 PLATFORM BASED PRODUCTS 152
- 10.2.3 KITS AND REAGENTS 153
- 10.2.4 OTHER CONSUMABLES 153
10.3 DIAGNOSTIC AND PREDICTIVE 153
- 10.3.1 INSTRUMENT BASED PRODUCTS 154
- 10.3.2 PLATFORM BASED PRODUCTS 154
- 10.3.3 KITS AND REAGENTS 154
- 10.3.4 OTHER CONSUMABLES 154
10.4 PROGNOSTIC 154
- 10.4.1 INSTRUMENT BASED PRODUCTS 155
- 10.4.2 PLATFORM BASED PRODUCTS 155
- 10.4.3 KITS AND REAGENTS 155
- 10.4.4 OTHER CONSUMABLES 156
10.5 RESEARCH 156
- 10.5.1 INSTRUMENT BASED PRODUCTS 157
- 10.5.2 PLATFORM BASED PRODUCTS 157
- 10.5.3 KITS AND REAGENTS 157
- 10.5.4 OTHER CONSUMABLES 157

11 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE 158

11.1 OVERVIEW 159
11.2 STAGE IV 161
11.3 STAGE I 162
11.4 STAGE III 163
11.5 STAGE II 164
11.6 STAGE 0 165

12 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TECHNOLOGY 166

12.1 OVERVIEW 167
12.2 FLUORESCENT IN SITU HYBRIDIZATION 169
12.3 NEXT GENERATION SEQUENCING 170
12.4 FLUORIMMUNOASSAY 171
12.5 COMPARATIVE GENOMIC HYBRIDIZATION 172
12.6 IMMUNOHISTOLOCHEMICAL 172
12.7 OTHER 173

13 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY PRODUCT 174

13.1 OVERVIEW 175
13.2 INSTRUMENT BASED PRODUCTS 177
- 13.2.1 IMAGING 178
- 13.2.2 BIOPSY 178
13.3 PLATFORM BASED PRODUCTS 179
- 13.3.1 NEXT-GENERATION SEQUENCING 180
- 13.3.2 MICROARRAYS 180
- 13.3.3 PCR 180
- 13.3.4 OTHERS 180
13.4 KITS AND REAGENTS 180
- 13.4.1 NON-HODGKIN LYMPHOMA PANELS 181
- 13.4.2 IMMUNOHISTOCHEMISTRY STAINS 181
- 13.4.3 OTHERS 181
13.5 OTHER CONSUMABLES 182

14 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY END USER 183

14.1 OVERVIEW 184
14.2 HOSPITALS 186
14.3 DIAGNOSTIC CENTERS 187
14.4 CANCER RESEARCH CENTERS 188
14.5 ACADEMIC INSTITUTES 189
14.6 AMBULATORY SURGICAL CENTERS 189
14.7 OTHERS 190

15 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 191

15.1 OVERVIEW 192
15.2 DIRECT TENDER 194
15.3 RETAIL SALES 195
15.4 OTHERS 196

16 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION 197

16.1 NORTH AMERICA 198
- 16.1.1 U.S. 216
- 16.1.2 CANADA 228
- 16.1.3 MEXICO 240

17 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 252

17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 252

18 SWOT ANALYSIS 253

19 NORTH AMERICA NON-HODKIN LYMPHOMA DIAGNOSTICS MARKET 254

19.1 CANON MEDICAL SYSTEMS CORPORATION 254
- 19.1.1 COMPANY SNAPSHOT 254
- 19.1.2 REVENUE ANALYSIS 254
- 19.1.3 COMPANY SHARE ANALYSIS 255
- 19.1.4 PRODUCT PORTFOLIO 255
- 19.1.5 RECENT DEVELOPMENT 255
19.2 KONINKLIJKE PHILIPS N.V. 256
- 19.2.1 COMPANY SNAPSHOT 256
- 19.2.2 REVENUE ANALYSIS 256
- 19.2.3 COMPANY SHARE ANALYSIS 257
- 19.2.4 PRODUCT PORTFOLIO 257
- 19.2.5 RECENT DEVELOPMENTS 257
19.3 SIEMENS HEALTHCARE GMBH 258
- 19.3.1 COMPANY SNAPSHOT 258
- 19.3.2 REVENUE ANALYSIS 258
- 19.3.3 COMPANY SHARE ANALYSIS 259
- 19.3.4 PRODUCT PORTFOLIO 259
- 19.3.5 RECENT DEVELOPMENT 260
19.4 DANAHER. 261
- 19.4.1 COMPANY SNAPSHOT 261
- 19.4.2 REVENUE ANALYSIS 261
- 19.4.3 COMPANY SHARE ANALYSIS 262
- 19.4.4 PRODUCT PORTFOLIO 262
- 19.4.5 RECENT DEVELOPMENTS 263
19.5 BIO-RAD LABORATORIES, INC. 264
- 19.5.1 COMPANY SNAPSHOT 264
- 19.5.2 REVENUE ANALYSIS 264
- 19.5.3 COMPANY SHARE ANALYSIS 265
- 19.5.4 PRODUCT PORTFOLIO 265
- 19.5.5 RECENT DEVELOPMENT 265
19.6 AGILENT TECHNOLOGIES, INC. 266
- 19.6.1 COMPANY PROFILE 266
- 19.6.2 REVENUE ANALYSIS 266
- 19.6.3 PRODUCT PORTFOLIO 267
- 19.6.4 RECENT DEVELOPMENT 267
19.7 CENTOGENE N.V. 268
- 19.7.1 COMPANY SNAPSHOT 268
- 19.7.2 PRODUCT PORTFOLIO 268
- 19.7.3 RECENT DEVELOPMENT 268
19.8 F. HOFFMANN- LA ROCHE LTD 269
- 19.8.1 COMPANY SNAPSHOT 269
- 19.8.2 REVENUE ANALYSIS 269
- 19.8.3 PRODUCT PORTFOLIO 270
- 19.8.4 RECENT DEVELOPMENTS 270
19.9 GENERAL ELECTRIC COMPANY 271
- 19.9.1 COMPANY SNAPSHOT 271
- 19.9.2 REVENUE ANALYSIS 271
- 19.9.3 PRODUCT PORTFOLIO 272
- 19.9.4 RECENT DEVELOPMENTS 272

19.10 GENEDX, LLC 273
- 19.10.1 COMPANY SNAPSHOT 273
- 19.10.2 PRODUCT PORTFOLIO 273
- 19.10.3 RECENT DEVELOPMENT 273
19.11 GRAIL 274
- 19.11.1 COMPANY PROFILE 274
- 19.11.2 PRODUCT PORTFOLIO 274
- 19.11.3 RECENT DEVELOPMENT 274
19.12 HOLOGIC INC. 275
- 19.12.1 COMPANY SNAPSHOT 275
- 19.12.2 REVENUE ANALYSIS 275
- 19.12.3 PRODUCT PORTFOLIO 276
- 19.12.4 RECENT DEVELOPMENT 276
19.13 INVITAE CORPORATION 277
- 19.13.1 COMPANY PROFILE 277
- 19.13.2 REVENUE ANALYSIS 277
- 19.13.3 PRODUCT PORTFOLIO 278
- 19.13.4 RECENT DEVELOPMENT 278
19.14 NEUSOFT CORPORATION 279
- 19.14.1 COMPANY SNAPSHOT 279
- 19.14.2 REVENUE ANALYSIS 279
- 19.14.3 PRODUCT PORTFOLIO 280
- 19.14.4 RECENT DEVELOPMENT 280
19.15 NEOGENOMICS LABORATORIES 281
- 19.15.1 COMPANY SNAPSHOT 281
- 19.15.2 REVENUE ANALYSIS 281
- 19.15.3 PRODUCT PORTFOLIO 282
- 19.15.4 RECENT DEVELOPMENTS 282
19.16 PERKINELMER INC 283
- 19.16.1 COMPANY PROFILE 283
- 19.16.2 REVENUE ANALYSIS 283
- 19.16.3 PRODUCT PORTFOLIO 284
- 19.16.4 RECENT DEVELOPMENT 284
19.17 QIAGEN 285
- 19.17.1 COMPANY SNAPSHOT 285
- 19.17.2 REVENUE ANALYSIS 285
- 19.17.3 PRODUCT PORTFOLIO 286
- 19.17.4 RECENT DEVELOPMENT 286
19.18 SYSMEX CORPORATION 287
- 19.18.1 COMPANY SNAPSHOT 287
- 19.18.2 REVENUE ANALYSIS 287
- 19.18.3 PRODUCT PORTFOLIO 288
- 19.18.4 RECENT DEVELOPMENTS 288

20 QUESTIONNAIRE 289

21 RELATED REPORTS 293

LIST OF TABLES

TABLE 1 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 64
TABLE 2 NORTH AMERICA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 65
TABLE 3 NORTH AMERICA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 65
TABLE 4 NORTH AMERICA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 67
TABLE 5 NORTH AMERICA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 67
TABLE 6 NORTH AMERICA IMMUNOHISTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 68
TABLE 7 NORTH AMERICA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 69
TABLE 8 NORTH AMERICA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 69
TABLE 9 NORTH AMERICA GENETIC TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 70
TABLE 10 NORTH AMERICA CYTOGENETICS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 71
TABLE 11 NORTH AMERICA LUMBAR PUNCTURE (SPINAL TAP) IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 71
TABLE 12 NORTH AMERICA BLOOD TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 72
TABLE 13 NORTH AMERICA CYTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 73
TABLE 14 NORTH AMERICA OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 73
TABLE 15 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 77
TABLE 16 NORTH AMERICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 78
TABLE 17 NORTH AMERICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 78
TABLE 18 NORTH AMERICA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 79
TABLE 19 NORTH AMERICA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 80
TABLE 20 NORTH AMERICA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 81
TABLE 21 NORTH AMERICA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 82
TABLE 22 NORTH AMERICA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 83
TABLE 23 NORTH AMERICA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 84
TABLE 24 NORTH AMERICA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 25 NORTH AMERICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 85
TABLE 26 NORTH AMERICA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 86
TABLE 27 NORTH AMERICA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 87
TABLE 28 NORTH AMERICA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 88
TABLE 29 NORTH AMERICA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 89
TABLE 30 NORTH AMERICA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 90
TABLE 31 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 94
TABLE 32 NORTH AMERICA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 95
TABLE 33 NORTH AMERICA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 95
TABLE 34 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 96
TABLE 35 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 97
TABLE 36 NORTH AMERICA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 37 NORTH AMERICA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 98
TABLE 38 NORTH AMERICA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 99
TABLE 39 NORTH AMERICA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 100
TABLE 40 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 104
TABLE 41 NORTH AMERICA STAGE IV IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 105
TABLE 42 NORTH AMERICA STAGE I IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 106
TABLE 43 NORTH AMERICA STAGE III IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 107
TABLE 44 NORTH AMERICA STAGE II IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION 107
TABLE 45 NORTH AMERICA STAGE 0 IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 108
TABLE 46 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 112
TABLE 47 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 113
TABLE 48 NORTH AMERICA NEXT GENERATION SEQUENCING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 114
TABLE 49 NORTH AMERICA FLUORIMMUNOASSAY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 114
TABLE 50 NORTH AMERICA COMPARATIVE GENOMIC HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 115
TABLE 51 NORTH AMERICA IMMUNOHISTOCHEMICAL IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 116
TABLE 52 NORTH AMERICA OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 116
TABLE 53 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 120
TABLE 54 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 121
TABLE 55 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 121
TABLE 56 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 122
TABLE 57 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 123
TABLE 58 NORTH AMERICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 124
TABLE 59 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 124
TABLE 60 NORTH AMERICA OTHER CONSUMABLES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)) 125
TABLE 61 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 129
TABLE 62 NORTH AMERICA HOSPITALS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 130
TABLE 63 NORTH AMERICA DIAGNOSTIC CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 131
TABLE 64 NORTH AMERICA CANCER RESEARCH CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 131
TABLE 65 NORTH AMERICA ACADEMIC INSTITUTES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 132
TABLE 66 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 133
TABLE 67 NORTH AMERICA OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 133
TABLE 68 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 137
TABLE 69 NORTH AMERICA DIRECT TENDER IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 138
TABLE 70 NORTH AMERICA RETAIL SALES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 138
TABLE 71 NORTH AMERICA OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 139
TABLE 72 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 146
TABLE 73 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 146
TABLE 74 NORTH AMERICA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 147
TABLE 75 NORTH AMERICA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 147
TABLE 76 NORTH AMERICA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 147
TABLE 77 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 148
TABLE 78 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 148
TABLE 79 NORTH AMERICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 148
TABLE 80 NORTH AMERICA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 149
TABLE 81 NORTH AMERICA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 149
TABLE 82 NORTH AMERICA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 149
TABLE 83 NORTH AMERICA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 150
TABLE 84 NORTH AMERICA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 150
TABLE 85 NORTH AMERICA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 150
TABLE 86 NORTH AMERICA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 151
TABLE 87 NORTH AMERICA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 151
TABLE 88 NORTH AMERICA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 151
TABLE 89 NORTH AMERICA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 152
TABLE 90 NORTH AMERICA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 152
TABLE 91 NORTH AMERICA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 152
TABLE 92 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 153
TABLE 93 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 153
TABLE 94 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 153
TABLE 95 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 153
TABLE 96 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 154
TABLE 97 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 154
TABLE 98 NORTH AMERICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 154
TABLE 99 NORTH AMERICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 154
TABLE 100 NORTH AMERICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 155
TABLE 101 NORTH AMERICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 155
TABLE 102 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 155
TABLE 103 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 156
TABLE 104 NORTH AMERICA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 156
TABLE 105 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 156
TABLE 106 NORTH AMERICA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 157
TABLE 107 NORTH AMERICA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 157
TABLE 108 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 157
TABLE 109 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 158
TABLE 110 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 159
TABLE 111 U.S. IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 159
TABLE 112 U.S. BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 160
TABLE 113 U.S. BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 160
TABLE 114 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 160
TABLE 115 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 161
TABLE 116 U.S. AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 161
TABLE 117 U.S. DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 161
TABLE 118 U.S. ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 162
TABLE 119 U.S. MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 162
TABLE 120 U.S. PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 162
TABLE 121 U.S. LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 163
TABLE 122 U.S. BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 163
TABLE 123 U.S. INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 163
TABLE 124 U.S. FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 164
TABLE 125 U.S. CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 164
TABLE 126 U.S. MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 164
TABLE 127 U.S. LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
TABLE 128 U.S. SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
TABLE 129 U.S. NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
TABLE 130 U.S. INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 166
TABLE 131 U.S. INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 166
TABLE 132 U.S. INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 166
TABLE 133 U.S. PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 166

LIST OF FIGURES

FIGURE 1 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION 31
FIGURE 2 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DATA TRIANGULATION 34
FIGURE 3 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DROC ANALYSIS 35
FIGURE 4 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 36
FIGURE 5 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 36
FIGURE 6 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MULTIVARIATE MODELLING 37
FIGURE 7 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 38
FIGURE 8 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 39
FIGURE 9 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID 40
FIGURE 10 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 41
FIGURE 11 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION 45
FIGURE 12 THE INCREASING PREVALENCE OF NON-HODGKIN LYMPHOMA AND INCREASED RESEARCH & DEVELOPMENT IN NON-HODGKIN LYMPHOMA DIAGNOSTICS ARE DRIVING THE NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 46
FIGURE 13 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN 2021 & 2028 46
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET 53
FIGURE 15 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2022 61
FIGURE 16 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 62
FIGURE 17 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030) 62
FIGURE 18 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE 63
FIGURE 19 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2022 74
FIGURE 20 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2023-2030 (USD MILLION) 75
FIGURE 21 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, CAGR (2023-2030) 75
FIGURE 22 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, LIFELINE CURVE 76
FIGURE 23 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2022 91
FIGURE 24 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 92
FIGURE 25 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2023-2030) 92
FIGURE 26 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE 93
FIGURE 27 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2022 101
FIGURE 28 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION) 102
FIGURE 29 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030) 102
FIGURE 30 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE 103
FIGURE 31 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2022 109
FIGURE 32 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 110
FIGURE 33 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, CAGR (2023-2030) 110
FIGURE 34 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, LIFELINE CURVE 111
FIGURE 35 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2022 117
FIGURE 36 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2023-2030 (USD MILLION) 118
FIGURE 37 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, CAGR (2023-2030) 118
FIGURE 38 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, LIFELINE CURVE 119
FIGURE 39 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2022 126
FIGURE 40 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION) 127
FIGURE 41 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030) 127
FIGURE 42 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE 128
FIGURE 43 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2022 134
FIGURE 44 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 135
FIGURE 45 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 135
FIGURE 46 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 136
FIGURE 47 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SNAPSHOT (2022) 141
FIGURE 48 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022) 143
FIGURE 49 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 143
FIGURE 50 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 144
FIGURE 51 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 144
FIGURE 52 NORTH AMERICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 194